Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Combination chemotherapy (CMFVP) versus L‐phenylalanine mustard (L‐PAM) for operable breast cancer with positive axillary nodes. A southwest oncology group study
Cancer, Volume 50, No. 3, Year 1982
Notification
URL copied to clipboard!
Description
The Southwest Oncology Group in a prospective randomized study compared one year of adjuvant combination chemotherapy with continuous CMFVP to two years of intermittent L‐PAM in women with operable breast cancer with histologically positive axillary lymph nodes. In fully evaluable patients with a 42‐month median and 30‐month minimum follow‐up, treatment failures have occurred in 26% of 145 receiving CMFVP and 47% of 167 women given L‐PAM (P = 0.002). Disease‐free survival times were significantly longer with CMFVP than with L‐PAM in the following subgroups: premenopausal women (P = 0.002), postmenopausal women (P = 0.002), women with 1–3 involved axillary nodes (P = 0.003), and women with four or more involved axillary nodes (P = 0.002). CMFVP was effective in pre‐ and postmenopausal women. There is a significant difference in survival in favor of CMFVP compared to L‐PAM (P = 0.005). The life table estimates of survival at 42 months are 86% for women on the CMFVP treatment arm and 73% for women on the L‐PAM treatment arm. There was no correlation between the interval from mastectomy to onset of chemotherapy (between one and six weeks) and recurrence rates. Acute toxicity with both treatment arms was moderate and reversible. These results show that continuous CMFVP is superior to intermittent L‐PAM in decreasing recurrences and increasing survival in both pre‐ and postmenopausal women with operable breast cancer with histologically involved axillary nodes. Copyright © 1982 American Cancer Society
Authors & Co-Authors
Glucksberg, Harold
United States, Seattle
University of Washington School of Medicine
Rivkin, Saul Eugene
United States, Seattle
Swedish Medical Center, Seattle
Rasmussen, Shelley
United States, Houston
Statistical Office
Tranum, Bill L.
United States, Little Rock
University of Arkansas for Medical Sciences
Gad-El-Mawla, Nazli M.
Egypt, Giza
National Cancer Institute
Costanzi, John J.
United States, Galveston
The University of Texas Medical Branch at Galveston
Hoogstraten, Barth
United States, Kansas City
University of Kansas Medical Center
Athens, John
United States, Salt Lake City
University of Utah Health Sciences
Maloney, Thomas R.
United States, San Antonio
Wilford Hall Ambulatory Surgical Center
McCracken, Joseph
United States, Fort Sam Houston
Brooke Army Medical Center
Vaughn, Clarence B.
United States, Southfield
Providence Hospital, Southfield
Statistics
Citations: 11
Authors: 11
Affiliations: 11
Identifiers
Doi:
10.1002/1097-0142(19820801)50:3<423::AID-CNCR2820500307>3.0.CO;2-O
ISSN:
0008543X
e-ISSN:
10970142
Research Areas
Cancer
Study Design
Cohort Study
Participants Gender
Female